The online version of this article (doi:10.1007/s40262-016-0399-y) contains supplementary material, which is available to authorized users.
E. Peters, J. A. A. C. Heuberger and R. Tiessen contributed equally to this work.
J. Stevens and P. Pickkers share senior authorship of this article.
Previous clinical trials have suggested that bovine intestinal alkaline phosphatase has renal protective effects in patients with sepsis-associated acute kidney injury. We conducted a first-in-human study to investigate the pharmacokinetics, safety and tolerability of a novel human recombinant alkaline phosphatase (recAP), and we developed a population pharmacokinetic model to support dose selection for future patient studies.
In a randomized, double-blind, placebo-controlled, phase I trial, healthy volunteers received a single dose of recAP (200, 500, 1000 or 2000 U/kg; n = 33; 3:1 ratio) or multiple doses of recAP (500 or 1000 U/kg; n = 18; 2:1 ratio) via a 1-h intravenous infusion on three consecutive days. Serum recAP concentrations, alkaline phosphatase (AP) activity levels and anti-drug antibodies were measured, and safety parameters were monitored. A population pharmacokinetic model was developed, and simulations were performed to guide dose selection for a phase IIa/b trial.
Peak concentrations of recAP and peak AP activity were reached at the end of the 1-h infusion and showed a rapid decline, with about 10 % of the maximum concentration remaining at 4 h and less than 5 % remaining 24 h post-start. RecAP treatment was generally well tolerated, and anti-drug antibodies could not be detected in the serum up to 2 weeks post-injection after a single dose, or up to 3 weeks post-injection after multiple doses. A four-compartment model best described the pharmacokinetics of recAP administration, with moderate inter-individual variability on the central volume of distribution and elimination rate constant. Simulations showed that 1-h intravenous infusions of 250, 500 and 1000 U/kg recAP once every 24 h for three consecutive days constituted the dosing regimen that best met the criteria for dose selection in patient studies.
RecAP did not raise any safety concerns when administered to healthy volunteers. A population pharmacokinetic model was developed to support dose selection for patient studies.
Supplementary material 1 (DOC 61 kb)40262_2016_399_MOESM1_ESM.doc
Case J, Khan S, Khalid R, Khan A. Epidemiology of acute kidney injury in the intensive care unit. Crit Care Res Prac. 2013;2013:479730.
Oppert M, Engel C, Brunkhorst FM, Bogatsch H, Reinhart K, Frei U, et al. Acute renal failure in patients with severe sepsis and septic shock—a significant independent risk factor for mortality: results from the German Prevalence Study. Nephrol Dial Transpl. 2008;23(3):904–9. CrossRef
Millan JL. Alkaline phosphatases: structure, substrate specificity and functional relatedness to other members of a large superfamily of enzymes. Purinergic Signalg. 2006;2(2):335–41. CrossRef
Heemskerk S, Masereeuw R, Moesker O, Bouw MP, van der Hoeven JG, Peters WH, et al. Alkaline phosphatase treatment improves renal function in severe sepsis or septic shock patients. Crit Care Med. 2009;37(2):417–23, e1.
R Development Core Team. R: a language and environment for statistical computing. Vienna: R Foundation for Statistical Computing; 2010.
International Conference on Harmonisation. Introductory guide: MedDRA version 16.1. McLean: MedDRA Maintenance and Support Services Organization; 2013. http://www.meddra.org/sites/default/files/guidance/file/intguide_16_1_english.pdf. Accessed 3 Mar 2016.
Pearson K. Note on regression and inheritance in the case of two parents. Proc R Soc Lond. 1895;58(58):240–2. CrossRef
US Food and Drug Administration [FDA] Center for Drug Evaluation and Research. Guidance for industry: population pharmacokinetics. Rockville: FDA; 1999. http://www.fda.gov/downloads/ScienceResearch/SpecialTopics/WomensHealthResearch/UCM133184.pdf. Accessed 1 Mar 2016.
European Medicines Agency [EMA] Committee for Medicinal Products for Human Use. Guideline on reporting the results of population pharmacokinetic analyses. London: European Medicines Agency; 2007. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003067.pdf. Accessed 3 Mar 2016.
McComb RB, Bowers GN Jr, Posen S. Isoenzymes. In: Alkaline phosphatase. New York: Plenum Press; 1979. p. 415.
- Pharmacokinetic Modeling and Dose Selection in a Randomized, Double-Blind, Placebo-Controlled Trial of a Human Recombinant Alkaline Phosphatase in Healthy Volunteers
Jules A. A. C. Heuberger
Andrea van Elsas
- Springer International Publishing